Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Completed · Phase 2

Conditions studied: Head and Neck Cancer

In brief

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving bevacizumab together with docetaxel and radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving bevacizumab together with docetaxel and radiation therapy works in treating patients with stage III or stage IV head and neck cancer.

Key facts

Study ID

NCT00281840

Run by

Case Comprehensive Cancer Center

People needed

30

Starts

2005-09-01

Expected to finish

2012-12-01

Last updated by the study team

2015-06-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center — Cleveland, Ohio, United States
• Lake/University Ireland Cancer Center — Mentor, Ohio, United States
• Southwest General Health Center — Middleburg Heights, Ohio, United States
• UHHS Chagrin Highlands Medical Center — Orange Villager, Ohio, United States
• UHHS Westlake Medical Center — Westlaker, Ohio, United States
• UPMC Cancer Centers — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.